Cerebrospinal fluid biomarkers of Alzheimer’s disease

Alzheimer’s disease (AD) is a fatal neurodegenerative disorder that takes about a decade to develop, making early diagnosis possible. Clinically, the diagnosis of AD is complicated, costly, and inaccurate, so it is urgent to find specific biomarkers. Due to its multifactorial nature, a panel of biomarkers for the multiple pathologies of AD, such as cerebral amyloidogenesis, neuronal dysfunction, synapse loss, oxidative stress, and inflammation, are most promising for accurate diagnosis. Highly sensitive and high-throughput proteomic techniques can be applied to develop a panel of novel biomarkers for AD. In this review, we discuss the metabolism and diagnostic performance of the well-established core candidate cerebrospinal fluid (CSF) biomarkers (β-amyloid, total tau, and hyperphosphorylated tau). Meanwhile, novel promising CSF biomarkers, especially those identified by proteomics, updated in the last five years are also extensively discussed. Furthermore, we provide perspectives on how biomarker discovery for AD is evolving.

[1]  E. Wolters,et al.  Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease , 1995, Annals of neurology.

[2]  A. Procter,et al.  Possible neurotransmitter basis of behavioral changes in alzheimer's disease , 1988, Annals of neurology.

[3]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[4]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[5]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[6]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[7]  D. Geldmacher,et al.  Clock Drawing Test in Very Mild Alzheimer's Disease , 1998, Journal of the American Geriatrics Society.

[8]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[9]  H. Hampel,et al.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[10]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[11]  Colin L Masters,et al.  Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.

[12]  C. Humpel,et al.  Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients , 2009, Journal of neurochemistry.

[13]  B. Garcia,et al.  Proteomics , 2011, Journal of biomedicine & biotechnology.

[14]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[15]  Jeffrey L. Cummings,et al.  Biomarkers in Alzheimer's disease drug development , 2011, Alzheimer's & Dementia.

[16]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[18]  K. Jellinger,et al.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients , 2009, Journal of Neural Transmission.

[19]  D. Holtzman,et al.  CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease , 2012, Neurology.

[20]  A. Kakita,et al.  Increased Levels of Soluble LR11 in Cerebrospinal Fluid of Patients with Alzheimer Disease , 2010, Dementia and Geriatric Cognitive Disorders.

[21]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[22]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[23]  J. Touchon,et al.  Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer’s disease and other dementias , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[24]  A. Fagan,et al.  Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease , 2011, Annals of neurology.

[25]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[26]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. de Strooper,et al.  BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. , 2013, Current Alzheimer research.

[28]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[29]  Douglas Galasko,et al.  Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers , 2011, NeuroMolecular Medicine.

[30]  P. Deyn,et al.  Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia , 2008, Neurobiology of Aging.

[31]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[32]  M. Pallàs,et al.  Molecular and biochemical features in Alzheimer's disease. , 2006, Current pharmaceutical design.

[33]  P. Southwick,et al.  Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. , 1996, Journal of neurochemistry.

[34]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[35]  K. Suk,et al.  Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases , 2009, Brain Research.

[36]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[37]  Y. Agid,et al.  Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. , 1993, Archives of neurology.

[38]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[39]  Amity E. Green,et al.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects , 2010, Neurobiology of Aging.

[40]  E. Peskind,et al.  S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10 , 2009, PloS one.

[41]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[42]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[43]  B Engvall,et al.  Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression , 1999, Annals of neurology.

[44]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[45]  Khadija Iqbal,et al.  Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. , 2000, Journal of neural transmission. Supplementum.

[46]  K. Blennow,et al.  Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. , 2002, Dementia and Geriatric Cognitive Disorders.

[47]  Kurt Giles,et al.  Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer's disease , 2011, Proceedings of the National Academy of Sciences.

[48]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[49]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[50]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[51]  J. Cocho,et al.  Neuropeptide Kyotorphin (Tyrosyl-Arginine) has Decreased Levels in the Cerebro-Spinal Fluid of Alzheimer’s Disease Patients: Potential Diagnostic and Pharmacological Implications , 2013, Front. Aging Neurosci..

[52]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[53]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[54]  K. Blennow CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment , 2005, Expert review of molecular diagnostics.

[55]  B. Winblad,et al.  Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation , 1995, Neuroscience Letters.

[56]  Kaj Blennow,et al.  β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease , 2002, Peptides.

[57]  H. Mischak,et al.  Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers , 2011, PloS one.

[58]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[59]  Alan D. Baddeley,et al.  Analysis of the episodic memory deficit in early Alzheimer's disease: Evidence from the doors and people test , 1996, Neuropsychologia.

[60]  P. Lewczuk,et al.  Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. , 2004, Neurobiology of aging.

[61]  C. Geula,et al.  Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. , 1993, Archives of neurology.

[62]  L. Thal,et al.  Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients , 2000, Neurobiology of Aging.

[63]  Christophe Lemetre,et al.  Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. , 2012, Journal of Alzheimer's disease : JAD.

[64]  A. Kertesz,et al.  On drawing impairment in Alzheimer's disease. , 1991, Archives of neurology.

[65]  K. Blennow,et al.  Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease , 2010, PloS one.

[66]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[67]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[68]  Katharina Buerger,et al.  Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.

[69]  K. Blennow,et al.  A beta 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer ' s Disease , 2010 .

[70]  L. Buée,et al.  Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-β1–42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model , 2012, The Journal of Neuroscience.

[71]  P. Caramelli,et al.  Chemokines in CSF of Alzheimer's disease patients. , 2011, Arquivos de neuro-psiquiatria.

[72]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[73]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[74]  R. Béné,et al.  Nano-HPLC–MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients—a pilot study , 2010, Analytical and bioanalytical chemistry.

[75]  Ge Li,et al.  Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease , 2011, PloS one.

[76]  I. Grundke‐Iqbal,et al.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. , 2002, The American journal of pathology.

[77]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[78]  S. Prusiner,et al.  Erratum: Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer's disease (Proceedings of the National Academy of Sciences of the United States of America (2011) 108 (2528-2533) DOI: 10.1073/pnas. 1019034108) , 2014 .

[79]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[80]  W. M. van der Flier,et al.  BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. , 2010, Journal of Alzheimer's disease : JAD.

[81]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.

[82]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[83]  K Patterson,et al.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.

[84]  P. Southwick,et al.  Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease , 1996 .

[85]  1 The GloBAl eCoNomiC impACT oF demeNTiA Alzheimer ’ s diseAse internAtionAl World Alzheimer report 2010 the GlobAl economic impAct of dementiA , 2022 .

[86]  H. Braak,et al.  Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis , 1996, Acta Neuropathologica.

[87]  I. Grundke‐Iqbal,et al.  Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients , 2002, Neuroscience Letters.

[88]  S. Sisodia Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[89]  R. Perneczky,et al.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[90]  G. Evin,et al.  Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides , 2002, Peptides.

[91]  W. Maetzler,et al.  Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. , 2010, Current Alzheimer research.

[92]  W. M. van der Flier,et al.  Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. , 2010, Journal of Alzheimer's disease : JAD.

[93]  S. Hirai,et al.  Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. , 1998, Journal of the neurological sciences.

[94]  K. Blennow,et al.  Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease , 2011, Molecular Neurodegeneration.

[95]  J. Morris,et al.  Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type , 2002, Alzheimer disease and associated disorders.

[96]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[97]  Sanjeeva Srivastava,et al.  Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.

[98]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[99]  M. Michalopoulou,et al.  Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[100]  K. Grzeschik,et al.  The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor , 1987 .

[101]  J. Wegiel,et al.  Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[102]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[103]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.